GL1X · GenesisL1 explorer

Research workbench

Crystal structure of braf (R509H) kinase domain bound to AZ628

Analyse Crystal structure of braf (R509H) kinase domain bound to AZ628 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4RZW
Type
protein
Length
503 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
SERINE/THREONINE-protein kinase B-RAF
EC
2.7.11.1
UniProt
P15056
Ligands
B1E
Pockets
5 · best druggability 0.71

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASERINE/THREONINE-protein kinase B-RAF (EC 2.7.11.1)protein25141% helix, 17% strandP15056
BSERINE/THREONINE-protein kinase B-RAF (EC 2.7.11.1)protein25239% helix, 15% strandP15056

Ligands and binding sites

  • B1E · 3-(2-cyanopropan-2-yl)-N-{4-methyl-3-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}benzamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 5 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14090.710.8237B1E
24230.700.8145B1E
3540.640.9422empty
4950.590.8720empty
51110.560.8422empty

Interfaces

1 interface between chains.

  • A–B · 1354 Ų buried · 13 hydrogen bonds · protein-protein

Compared structures

  • 4RZW · Crystal structure of BRAF (R509H) kinase domain bound to AZ628 · the same entry in another collection · chain A against A, TM-score 1.00
  • P15056 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase B-RAF (P15056) · a predicted model of the same protein · chain B against A, TM-score 0.94

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.